Work-Sharing Between Patent Offices: Key To Reducing Backlog, Or Harmonisation Threat? 05/11/2014 by Catherine Saez, Intellectual Property Watch 1 Comment Quality of patents is an issue that has been repeatedly discussed at the World Intellectual Property Organization committee on patent law, which is meeting this week.
Limitations And Exceptions To Patent Rights Discussed In WIPO Committee 04/11/2014 by Catherine Saez, Intellectual Property Watch 1 Comment The World Intellectual Property Organization patent law committee this week is addressing a range of issues including patent quality, technology transfer for medicine production, limitations and exceptions to patents, and the confidentiality of communications between clients and their patent advisors.
WTO Works To Make Vast Store Of TRIPS Information Easier To Use 03/11/2014 by Intellectual Property Watch Leave a Comment The World Trade Organization is taking steps to make the vast store of information shared by WTO members in the Council on Trade-Related Aspects of Intellectual Property Rights (TRIPS) easier to use.
TRIPS Council Debates: Tobacco Packaging, Non-Violation Disputes, Innovation, Health Waiver, UNCTAD 30/10/2014 by Catherine Saez, Intellectual Property Watch 1 Comment This week’s meeting of the World Trade Organization body governing intellectual property issues addressed a long agenda, reflecting continued divergence on regular items, such as complaints that do not involve breach of a WTO agreement, a health waiver, and sustained discussions on plain packaging for tobacco products.
European Commission Holds Consultation On Patents And Standards 29/10/2014 by Intellectual Property Watch Leave a Comment The European Commission Directorate General for Enterprise and Industry is gathering stakeholder input on standardisation and intellectual property rights, in order to assess the current framework on patents and standard and look at how it should evolve. Standard-setting cuts across many organisations at the national, European and international levels. Views are being sought until January 2015.
First Innovation Fair Hosted At WTO, Draws Diverse Projects With IP In Mind 29/10/2014 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Trade Organization hosted an Innovation Fair on 28 October, gathering inventors, supporting agencies, and patent offices. A number of inventions were displayed and explained, from concrete walls to motorisation for bicycles.
WHO Ebola Vaccine Meeting Draws Commitment From Pharma, Donors; MSF Sees Need For Concrete Actions 24/10/2014 by Catherine Saez, Intellectual Property Watch Leave a Comment A high-level meeting convened by the World Health Organization yesterday on the issue of access to and financing of Ebola vaccines resulted in a set of commitments, though not with sufficient urgency for those working on the ground. The pharmaceutical industry committed to scale up production, while donors pledged funds without disclosing how deep their pockets might be.
USPTO Director-Nominee Lee Calls For ‘Responsible Stewardship’ Of Patent System 23/10/2014 by William New, Intellectual Property Watch 1 Comment In perhaps her first big speech since being nominated by President Obama to head the United States Patent and Trademark Office (USPTO), Michelle Lee today told an industry meeting today to use the patent system responsibly and with balance. The agency is embarking on a new global effort to streamline processes and improve quality. And for the first time in a long time, she said, USPTO has the financial resources to do it.
Life Sciences Stakeholders Assess Accessing Emerging Markets 23/10/2014 by Magda Voltolini for Intellectual Property Watch 1 Comment PARIS –Life sciences stakeholders at a recent conference explored matters associated with market access in the BRICS (Brazil, Russia, India, China, South Africa) and in the Middle East and North Africa regions.
Little-Known Case May Dramatically Change US Patent System 22/10/2014 by Steven Seidenberg for Intellectual Property Watch 1 Comment The patent case recently argued before the US Supreme Court is relatively unknown, and for good reason. It involves no exciting new technology. It has no controversial patent claims (e.g., covering human genes). However, Teva Pharms. USA v. Sandoz, Inc. could produce major changes in America’s patent system.